Home LiteratureArticle Details
PMID: 35190740 Published · epublish English Journal Article

Targets and Potential Mechanism of Scutellaria baicalensis in Treatment of Primary Hepatocellular Carcinoma Based on Bioinformatics Analysis.

Journal of oncology ·Vol. 2022 ·2022-00-00 ·页码 8762717

Liu D, Wang Z, Zhong L, Xie C, Huang X, Zhi Y, Zhang Y, Liang J, Shi Z, Huang J, Zhang S, Zhang J, Ding F

Abstract

To analyze the target and potential mechanism of Scutellaria baicalensis (SB) in the treatment of HCC based on bioinformatics, so as to provide suggestions for the diagnosis, treatment, and drug development of hepatocellular carcinoma (HCC). The regulated gene targets of SB were screened by gene expression pattern clustering and differential analysis of gene expression data of HepG2 cells treated with SB at 0 h, 1 h, 3 h, 6 h, 12 h, and 24 h. The module genes related to HCC were identified by the weighted gene coexpression network analysis (WGCNA). KEGG and GO enrichment were used to analyze the molecular function and structure of the module, and GSEA was used to evaluate the different functional pathways between normal people and patients with HCC. Then, the module gene was used for univariate Cox proportional hazard analysis and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis to build a prognostic model. The protein-protein interaction network (PPI) was used to analyze the core genes regulated by SB (CGRSB) of the module, and the survival curve revealed the CGRSB impact on patient survival. The CIBERSORT algorithm combined with correlation analysis to explore the relationship between CGRSB and immune infiltration. Finally, the single-cell sequencing technique was used to analyze the distribution of CGRSB at the cellular level. SB could regulate 903 genes, of which 234 were related to the occurrence of HCC. The prognosis model constructed by these genes has a good effect in evaluating the survival of patients. KEGG and GO enrichment analysis showed that the regulation of SB on HCC mainly focused on some cell proliferation, apoptosis, and immune-related functions. GSEA enrichment analysis showed that these functions are related to the occurrence of HCC. A total of 24 CGRSB were obtained after screening, of which 13 were significantly related to survival, and most of them were unfavorable factors for patient survival. The correlation analysis of gene expression showed that most of CGRSB was significantly correlated with T cells, macrophages, and other functions. The results of single-cell analysis showed that the distribution of CGRSB in macrophages was the most. SB has high credibility in the treatment of HCC, such as CDK2, AURKB, RRM2, CENPE, ESR1, and PRIM2. These targets can be used as potential biomarkers for clinical diagnosis. The research also shows that the p53 signal pathway, MAPK signal pathway, apoptosis pathway, T cell receptor pathway, and macrophage-mediated tumor immunity play the most important role in the mechanism of SB in treating HCC.

作者与单位
共 13 位作者,点击展开单位 / ORCID
Liu Defu
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Wang Zhengjun
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Zhong Li
Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Guangzhou, China.
Xie Caoyu
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Huang Xiaonan
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Zhi Yaofeng
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangdong New South Stem Cell Regenerative Medicine Technology Co., Ltd, Guangzhou, China.
Zhang Yuzhuo
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangdong New South Stem Cell Regenerative Medicine Technology Co., Ltd, Guangzhou, China.
Liang Jiaying
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangdong New South Stem Cell Regenerative Medicine Technology Co., Ltd, Guangzhou, China.
Shi Zhenni
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Huang Jin
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Zhang Shuhe
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Zhang Jin ORCID
Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou, China. | Guangzhou University of Chinese Medicine, Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou, China.
Ding Fuping ORCID
Guangzhou University of Chinese Medicine, School of Nursing, Guangzhou, China.
Article Info
Journal
Journal of oncology
Abbr.
J Oncol
ISSN
1687-8450
Published
2022-00-00
电子出版
2022-00-12
页码
8762717
Language
English
Country/Region
Egypt
NLM ID
101496537
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com